|
|
|
|
Tenaya Therapeutics Inc (NASDAQ: TNYA) |
|
Price: $0.6096
$-0.01 
-1.677%
|
| Day's High:
| $0.6399999856948853
| Week Perf:
| -9.55 %
|
| Day's Low: |
$ 0.60 |
30 Day Perf: |
-12.41 % |
| Volume (M): |
3,721,032 |
52 Wk High: |
$ 2.35 |
| Volume (M$): |
$ 0 |
52 Wk Avg: |
$0.91 |
| Open: |
$0.63 |
52 Wk Low: |
$0.53 |
|
|
| Market Capitalization (Millions $) |
133 |
| Shares
Outstanding (Millions) |
218 |
| Employees |
70 |
| Revenues (TTM) (Millions $) |
1 |
| Net Income (TTM) (Millions $) |
-103 |
| Cash Flow (TTM) (Millions $) |
18 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Tenaya Therapeutics Inc is a biotechnology company focused on developing novel treatments for cardiovascular diseases. The company aims to leverage advancements in regenerative medicine and gene therapy to address unmet medical needs in the field. Tenaya Therapeutics is working on various innovative approaches, including reprogramming the body's own cells to regenerate damaged heart tissue and developing gene therapies that can reverse or prevent cardiovascular diseases. The company's ultimate goal is to improve outcomes and quality of life for patients suffering from heart conditions.
Company Address: 171 Oyster Point Boulevard South San Francisco 94080 CA
Company Phone Number: 825-6990 Stock Exchange / Ticker: NASDAQ TNYA
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Shares
Published Tue, Mar 4 2025 4:19 AM UTC
Tenaya Therapeutics Nets $52.5 Million in Public Offering Amid Anticipated TN-201 Gene Therapy Trial ResultsIn an important development within the biotechnology sector, Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biopharmaceutical organization focused on innovative treatments for heart disease, has successfully priced its underwritten public offering of 75 mil...
|
| Clinical Study
Published Mon, Dec 16 2024 9:30 PM UTC
Tenaya Therapeutics, a clinical-stage biotechnology company, is poised to make a significant announcement regarding its ongoing efforts to address hypertrophic cardiomyopathy (HCM) a genetic heart condition that leads to thickening of the heart muscle and can result in serious complications. On December 17, 2024, the company will share initial data from its MyPEAK-1 Phase ...
|
| Clinical Study
Published Mon, Nov 25 2024 1:30 PM UTC
Tenaya Therapeutics (NASDAQ: TNYA), a pioneering biotechnology company focusing on gene therapy and heart-related conditions, has announced the commencement of the RIDGE-1 Phase 1b clinical trial with the dosing of the first patient. This trial evaluates TN-401, an innovative AAV9-based gene therapy aimed at addressing Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) a...
|
| Shares
Published Tue, Nov 19 2024 1:01 PM UTC
Tenaya Therapeutics Announces Inducement Grants Amidst Strategic Reorganization to Drive Future GrowthIn a bid to solidify its position as a leader in developing innovative therapies for heart disease, Tenaya Therapeutics Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company, recently reported the issuance of inducement grants under NASDAQ Listing Rule 5635(c)(4). The ...
|
| Management Changes
Published Thu, Jun 27 2024 9:00 PM UTC
Tenaya Therapeutics Announces Research Leadership Updates
Tenaya Therapeutics, a leading biotechnology company focused on developing treatments for heart diseases, recently made significant changes to its research leadership team. In a press release, the company announced the promotion of Kathy Ivey, Ph.D., to Senior Vice President of Research, while Timothy Hoey, Ph.D.,...
|
Fundamental Analysis
| Per Share |
Current |
| Earnings (TTM) |
-0.54 $ |
| Revenues (TTM) |
0.01 $
|
| Cash Flow (TTM) |
0.08 $ |
| Cash |
0.36 $
|
| Book Value |
0.32 $
|
| Dividend (TTM) |
0 $ |
| Efficiency
|
Current |
| Revenue per Employee
(TTM) |
19,071 |
| Net
Income per Employee (TTM) |
-1,473,071 |
| Receivable Turnover Ratio (TTM) |
0.49 |
| Inventory Turnover Ratio (TTM) |
- |
| Asset Turnover Ratio (TTM) |
0.01 |
|
|
| Per Share |
|
| Earnings (TTM) |
-0.54 $
|
| Revenues (TTM) |
0.01 $ |
| Cash Flow (TTM) |
0.08 $ |
| Cash |
0.36 $
|
| Book Value |
0.32 $ |
| Dividend (TTM) |
0 $ |
|
|
| |
On March 18 2024 the Tenaya Therapeutics Inc provided following guidance
Tenaya Therapeutics Inc. has released its financial results for the fourth quarter and full year of 2023, along with a business update. The company is currently conducting the MyPeak-1 Phase 1b clinical trial of TN-201 for MYBPC3-associated hypertrophic cardiomyopathy (HCM), with initial data expected to be available in the second half of 2024.
The company's financial results for 2023 show promising progress in its efforts to develop innovative therapies for cardiovascular diseases. Tenaya Therapeutics remains focused on advancing its pipeline of novel drug candidates, including TN-201, which has the potential to address the unmet medical needs of patients with HCM.
With the upcoming data from ...
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.
7.32%